Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Receivables (2020 - 2025)

Rapid Micro Biosystems' Receivables history spans 6 years, with the latest figure at $5.5 million for Q3 2025.

  • For Q3 2025, Receivables rose 41.29% year-over-year to $5.5 million; the TTM value through Sep 2025 reached $5.5 million, up 41.29%, while the annual FY2024 figure was $7.5 million, 34.78% up from the prior year.
  • Receivables for Q3 2025 was $5.5 million at Rapid Micro Biosystems, down from $6.1 million in the prior quarter.
  • Across five years, Receivables topped out at $7.6 million in Q4 2024 and bottomed at $3.8 million in Q2 2023.
  • The 5-year median for Receivables is $5.1 million (2024), against an average of $5.0 million.
  • The largest annual shift saw Receivables dropped 22.35% in 2022 before it surged 43.0% in 2023.
  • A 5-year view of Receivables shows it stood at $5.4 million in 2021, then grew by 1.26% to $5.5 million in 2022, then increased by 2.08% to $5.6 million in 2023, then soared by 36.47% to $7.6 million in 2024, then decreased by 27.42% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Receivables are $5.5 million (Q3 2025), $6.1 million (Q2 2025), and $4.5 million (Q1 2025).